How Trump and the FDA Can Create a Pharmaceutical Manufacturing Renaissance

N/A by N/A is licensed under N/A N/A
In January, President Donald Trump said, “We have got to get our drug industry back.” Later that month, at a meeting in the Oval Office with executives of eight large innovator pharmaceutical companies, he said he wanted them to bring drug prices “way down,” and promised to curb regulations and lower tax rates to boost their competitiveness.

We are encouraged by these developments and consider these efforts as only the first steps by the president to understand the challenges of domestic pharmaceutical manufacturing. Furthermore, the nomination of Scott Gottlieb to lead the Food and Drug Administration adds to our encouragement. Gottlieb was the at the FDA during the time when the FDA launched its initiative the Pharmaceutical CGMPs for the 21st Century. To that end, we offer some points to consider in efficiently catalyzing a renaissance of a technologically modern, efficient, high quality, and profitable pharmaceutical manufacturing in the United States.

 
Article Photo Credit: N/A by N/A is licensed under N/A N/A
Sign Up for Our Email Newsletter

RECENT NEWS

AARP's Stop Rx Greed Campaign Should Focus on AARP's Rx Greed

AARP's Stop Rx Greed Campaign Should Focus on AARP's Rx Greed

...  Read more

FDA is smashing the status quo for regulatory science

FDA is smashing the status quo for regulatory science

The most potent way the FDA can enable innovation is by being a partner in advancing new approaches to both drug developm...  Read more

True Cost of Socialized Medicine & the Right Way to Hold Down the Cost of Healthcare

True Cost of Socialized Medicine & the Right Way to Hold Down the Cost of Healthcare

...  Read more

DRUGWONKS BLOG